Methicillin-resistant
Staphylococcus aureus (MRSA),
a virulent organism resistant to many drugs, is
responsible for most nosocomial and
community-acquired infections. It can cause
life-threatening diseases and treatment options are
limited. Effective diagnostic is a strategic key
element in the campaign against the spread of MRSA,
allowing better infection surveillance and control
measures as well as more efficient patient
treatment and/or isolation options.
The project relies on new advanced and proprietary
technologies that include: (1) robust and
clinically validated molecular protocol, (2)
microfluidics and nanoparticles based technologies.
The full integration and automation of complex
molecular assay in a single fluidic platform allows
a rapid and easy to use system that can be used at
“point-of-care”.
more info...
more info...
The
simplicity of the proposed technology allows
providing low cost systems, a prerequisite
condition for the large adoption of molecular tests
by hospitals.
The MagRSA platform will provide the possibility of both MRSA diagnostics and precise confirmation of bacteria subtype, both of which represent crucial steps for effective infection control and appropriate therapeutic decisions.
The MagRSA platform will provide the possibility of both MRSA diagnostics and precise confirmation of bacteria subtype, both of which represent crucial steps for effective infection control and appropriate therapeutic decisions.
The
Project
in
Yellow:
Staphylococcus aureus ;
in white:
Staphylococcus epidermitis
